EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--June 14, 2006--Savient Pharmaceuticals, Inc. (NASDAQ:SVNT - News) a specialty pharmaceutical company engaged in developing, manufacturing, and marketing pharmaceutical products that address unmet medical needs, announced today that it has dosed the first patient in its Phase 3 clinical studies of Puricase®, (PEG-uricase) for the treatment of patients with symptomatic gout for whom conventional therapy is contraindicated or has been ineffective.
